良性和恶性妇科疾病中肿瘤相关胰蛋白酶抑制剂（TATI）的血清水平。

Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases.

作者信息

Torre G C, Rembado R, Barbetti V, Vigliercio G P, Foglia M, Calabrese A, Corongiu F

机构信息

Department of Gynecology and Obstetrics, S. Corona Hospital, Pietra Ligure, Italy.

出版信息

Scand J Clin Lab Invest Suppl. 1991;207:15-8. doi: 10.3109/00365519109104620.

DOI:10.3109/00365519109104620

PMID:1780684

Abstract

The behavior of tumor-associated trypsin inhibitor (TATI) as a marker for gynecological cancer was studied in a control population and in patients with different benign and malignant diseases. When a cut-off level of 21.4 micrograms/l was used the specificity was 100% in patients with benign diseases. The sensitivity in patients with malignant tumors was low for cervical and corpus cancer, 13% and 14%, respectively, whereas it was 33% in all the ovarian malignant tumors, reaching 60% in the mucinous type. There was a clear correlation between TATI level and stage.

摘要

在一个对照人群以及患有不同良性和恶性疾病的患者中，研究了肿瘤相关胰蛋白酶抑制剂（TATI）作为妇科癌症标志物的行为。当采用21.4微克/升的临界值时，良性疾病患者的特异性为100%。恶性肿瘤患者中，宫颈癌和宫体癌的敏感性较低，分别为13%和14%，而在所有卵巢恶性肿瘤中为33%，黏液性类型中达到60%。TATI水平与分期之间存在明显相关性。